128 related articles for article (PubMed ID: 37260254)
1. Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability.
Shubin Z; Stanfield-Oakley S; Puangkaew J; Pitisutthithum P; Nitayaphan S; Gurunathan S; Sinangil F; Chariyalertsak S; Phanuphak N; Ake JA; O'Connell RJ; Vasan S; Akapirat S; Eller MA; Ferrari G; Paquin-Proulx D;
AIDS; 2023 Aug; 37(10):1519-1524. PubMed ID: 37260254
[TBL] [Abstract][Full Text] [Related]
2. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
Rerks-Ngarm S; Pitisuttithum P; Excler JL; Nitayaphan S; Kaewkungwal J; Premsri N; Kunasol P; Karasavvas N; Schuetz A; Ngauy V; Sinangil F; Dawson P; deCamp AC; Phogat S; Garunathan S; Tartaglia J; DiazGranados C; Ratto-Kim S; Pegu P; Eller M; Karnasuta C; Montefiori DC; Sawant S; Vandergrift N; Wills S; Tomaras GD; Robb ML; Michael NL; Kim JH; Vasan S; O'Connell RJ;
J Infect Dis; 2017 Apr; 215(8):1255-1263. PubMed ID: 28329190
[TBL] [Abstract][Full Text] [Related]
4. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
Akapirat S; Karnasuta C; Vasan S; Rerks-Ngarm S; Pitisuttithum P; Madnote S; Savadsuk H; Rittiroongrad S; Puangkaew J; Phogat S; Tartaglia J; Sinangil F; de Souza MS; Excler JL; Kim JH; Robb ML; Michael NL; Ngauy V; O'Connell RJ; Karasavvas N;
PLoS One; 2018; 13(4):e0196397. PubMed ID: 29702672
[TBL] [Abstract][Full Text] [Related]
5. Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.
Williams LD; Shen X; Sawant SS; Akapirat S; Dahora LC; Tay MZ; Stanfield-Oakley S; Wills S; Goodman D; Tenney D; Spreng RL; Zhang L; Yates NL; Montefiori DC; Eller MA; Easterhoff D; Hope TJ; Rerks-Ngarm S; Pittisuttithum P; Nitayaphan S; Excler JL; Kim JH; Michael NL; Robb ML; O'Connell RJ; Karasavvas N; Vasan S; Ferrari G; Tomaras GD;
PLoS Pathog; 2023 May; 19(5):e1011359. PubMed ID: 37256916
[TBL] [Abstract][Full Text] [Related]
6. Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial.
Tolbert WD; Van V; Sherburn R; Tuyishime M; Yan F; Nguyen DN; Stanfield-Oakley S; Easterhoff D; Bonsignori M; Haynes BF; Moody MA; Ray K; Ferrari G; Lewis GK; Pazgier M
mBio; 2020 Jun; 11(3):. PubMed ID: 32605979
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.
Karnasuta C; Akapirat S; Madnote S; Savadsuk H; Puangkaew J; Rittiroongrad S; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Tartaglia J; Sinangil F; Francis DP; Robb ML; de Souza MS; Michael NL; Excler JL; Kim JH; O'Connell RJ; Karasavvas N
AIDS Res Hum Retroviruses; 2017 May; 33(5):410-423. PubMed ID: 28006952
[TBL] [Abstract][Full Text] [Related]
8. Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.
Easterhoff D; Pollara J; Luo K; Tolbert WD; Young B; Mielke D; Jha S; O'Connell RJ; Vasan S; Kim J; Michael NL; Excler JL; Robb ML; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Wiehe K; Saunders KO; Montefiori DC; Tomaras GD; Moody MA; Pazgier M; Haynes BF; Ferrari G
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776278
[TBL] [Abstract][Full Text] [Related]
9. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
[TBL] [Abstract][Full Text] [Related]
10. IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees.
Fischinger S; Dolatshahi S; Jennewein MF; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Michael N; Vasan S; Ackerman ME; Streeck H; Alter G
JCI Insight; 2020 Nov; 5(21):. PubMed ID: 33031099
[TBL] [Abstract][Full Text] [Related]
11. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.
Chung AW; Ghebremichael M; Robinson H; Brown E; Choi I; Lane S; Dugast AS; Schoen MK; Rolland M; Suscovich TJ; Mahan AE; Liao L; Streeck H; Andrews C; Rerks-Ngarm S; Nitayaphan S; de Souza MS; Kaewkungwal J; Pitisuttithum P; Francis D; Michael NL; Kim JH; Bailey-Kellogg C; Ackerman ME; Alter G
Sci Transl Med; 2014 Mar; 6(228):228ra38. PubMed ID: 24648341
[TBL] [Abstract][Full Text] [Related]
12. RV144 HIV-1 vaccination impacts post-infection antibody responses.
Mdluli T; Jian N; Slike B; Paquin-Proulx D; Donofrio G; Alrubayyi A; Gift S; Grande R; Bryson M; Lee A; Dussupt V; Mendez-Riveria L; Sanders-Buell E; Chenine AL; Tran U; Li Y; Brown E; Edlefsen PT; O'Connell R; Gilbert P; Nitayaphan S; Pitisuttihum P; Rerks-Ngarm S; Robb ML; Gramzinski R; Alter G; Tovanabutra S; Georgiev IS; Ackerman ME; Polonis VR; Vasan S; Michael NL; Kim JH; Eller MA; Krebs SJ; Rolland M
PLoS Pathog; 2020 Dec; 16(12):e1009101. PubMed ID: 33290394
[TBL] [Abstract][Full Text] [Related]
13. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
[TBL] [Abstract][Full Text] [Related]
14. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
Easterhoff D; Moody MA; Fera D; Cheng H; Ackerman M; Wiehe K; Saunders KO; Pollara J; Vandergrift N; Parks R; Kim J; Michael NL; O'Connell RJ; Excler JL; Robb ML; Vasan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Liao HX; Ferrari G; Seaman MS; Montefiori DC; Tomaras GD; Harrison SC; Haynes BF
PLoS Pathog; 2017 Feb; 13(2):e1006182. PubMed ID: 28235027
[TBL] [Abstract][Full Text] [Related]
15. AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.
Huang Y; Seaton KE; Casapia M; Polakowski L; De Rosa SC; Cohen K; Yu C; Elizaga M; Paez C; Miner MD; Kelley CF; Maenza J; Keefer M; Lama JR; Sobieszczyk M; Buchbinder S; Baden LR; Lee C; Gulati V; Sinangil F; Montefiori D; McElrath MJ; Tomaras GD; Robinson HL; Goepfert P;
Vaccine; 2021 Jul; 39(33):4641-4650. PubMed ID: 34229888
[TBL] [Abstract][Full Text] [Related]
16. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
[TBL] [Abstract][Full Text] [Related]
17. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.
Gray GE; Huang Y; Grunenberg N; Laher F; Roux S; Andersen-Nissen E; De Rosa SC; Flach B; Randhawa AK; Jensen R; Swann EM; Bekker LG; Innes C; Lazarus E; Morris L; Mkhize NN; Ferrari G; Montefiori DC; Shen X; Sawant S; Yates N; Hural J; Isaacs A; Phogat S; DiazGranados CA; Lee C; Sinangil F; Michael NL; Robb ML; Kublin JG; Gilbert PB; McElrath MJ; Tomaras GD; Corey L
Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534016
[TBL] [Abstract][Full Text] [Related]
18. ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone.
Costanzo MC; Paquin-Proulx D; Schuetz A; Akapirat S; Shubin Z; Kim D; Wieczorek L; Polonis VR; Trinh HV; Rao M; Anenia H; Barrera MD; Boeckelman J; Nails B; Thapa P; Zemil M; Sacdalan C; Kroon E; Kaewboon B; Tipsuk S; Jongrakthaitae S; Gurunathan S; Sinangil F; Kim JH; Robb ML; Ake JA; O'Connell RJ; Pitisutthithum P; Nitayaphan S; Chariyalertsak S; Eller MA; Phanuphak N; Vasan S; ;
JCI Insight; 2023 May; 8(9):. PubMed ID: 37154156
[TBL] [Abstract][Full Text] [Related]
19. Innate immune cell activation after HIV-1 vaccine administration is associated with increased antibody production.
N'guessan KF; Machmach K; Swafford I; Costanzo MC; Wieczorek L; Kim D; Akapirat S; Polonis VR; Pitisuttithum P; Nitayaphan S; Gurunathan S; Sinangil F; Chariyalertsak S; Ake JA; O'connell RJ; Vasan S; Paquin-Proulx D
Front Immunol; 2024; 15():1339727. PubMed ID: 38420129
[TBL] [Abstract][Full Text] [Related]
20. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
Karasavvas N; Billings E; Rao M; Williams C; Zolla-Pazner S; Bailer RT; Koup RA; Madnote S; Arworn D; Shen X; Tomaras GD; Currier JR; Jiang M; Magaret C; Andrews C; Gottardo R; Gilbert P; Cardozo TJ; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Paris R; Greene K; Gao H; Gurunathan S; Tartaglia J; Sinangil F; Korber BT; Montefiori DC; Mascola JR; Robb ML; Haynes BF; Ngauy V; Michael NL; Kim JH; de Souza MS;
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1444-57. PubMed ID: 23035746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
